Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rivas

Showing results (211-220 of 239) with videos related to

Pageof 24
Sort By:
Frontiers in Immunology|March 14, 2022
Multi-Cellular Immunological Interactions Associated With COVID-19 InfectionsJitender S Verma, Claudia R Libertin, Yash Gupta, et al.
Journal of Medicinal Chemistry|March 5, 2019
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis TherapyWenlin Huang, Matthew A Hulverson, Ryan Choi, et al.
Rheumatology International|September 10, 2015
MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patientsJ F Mendoza Rincón, A K Rodríguez Elias, J M Fragoso, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Frontiers in Immunology|June 17, 2017
Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious DiseasesAriel L Rivas, Gabriel Leitner, Mark D Jankowski, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 23, 2020
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical TrialsGustavo Citera, Eduardo Mysler, Hugo Madariaga, et al.
Frontiers in Veterinary Science|January 5, 2024
Geo-temporal patterns to design cost-effective interventions for zoonotic diseases -the case of brucellosis in the country of GeorgiaAriel L Rivas, Stephen D Smith, V Basiladze, et al.
Cancers|November 13, 2021
The Utility of Differential Scanning Calorimetry Curves of Blood Plasma for Diagnosis, Subtype Differentiation and Predicted Survival in Lung CancerGabriela Schneider, Alagammai Kaliappan, Taylor Q Nguyen, et al.
Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Pageof 24

Showing results (211-220 of 239) with videos related to

Sort By:
Pageof 24
Frontiers in Immunology|March 14, 2022
Multi-Cellular Immunological Interactions Associated With COVID-19 InfectionsJitender S Verma, Claudia R Libertin, Yash Gupta, et al.
Journal of Medicinal Chemistry|March 5, 2019
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis TherapyWenlin Huang, Matthew A Hulverson, Ryan Choi, et al.
Rheumatology International|September 10, 2015
MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patientsJ F Mendoza Rincón, A K Rodríguez Elias, J M Fragoso, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Frontiers in Immunology|June 17, 2017
Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious DiseasesAriel L Rivas, Gabriel Leitner, Mark D Jankowski, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 23, 2020
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical TrialsGustavo Citera, Eduardo Mysler, Hugo Madariaga, et al.
Frontiers in Veterinary Science|January 5, 2024
Geo-temporal patterns to design cost-effective interventions for zoonotic diseases -the case of brucellosis in the country of GeorgiaAriel L Rivas, Stephen D Smith, V Basiladze, et al.
Cancers|November 13, 2021
The Utility of Differential Scanning Calorimetry Curves of Blood Plasma for Diagnosis, Subtype Differentiation and Predicted Survival in Lung CancerGabriela Schneider, Alagammai Kaliappan, Taylor Q Nguyen, et al.
Annals of the Rheumatic Diseases|September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceChristina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Pageof 24